Last reviewed · How we verify

NCT06282354

Telemedicine for Postoperative Follow-up After Oncological Surgeries

Status unknown Last updated 28 February 2024
What this trial tests

trial testing Type of post-operative appointment in Urologic Cancer in 200 participants. Status unknown.

Timeline
1 March 2024
Primary endpoint
15 August 2024
15 February 2025

Quick facts

Lead sponsorInstituto do Cancer do Estado de São Paulo
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment200
Start date1 March 2024
Primary completion15 August 2024
Estimated completion15 February 2025

Drugs / interventions tested

Conditions studied

Sponsor

Instituto do Cancer do Estado de São Paulo — full company profile →

Who can join

18 and older, any sex, with Urologic Cancer or Satisfaction, Patient. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will be a prospective, randomized, non-inferiority, open-label study, to be carried out at the Cancer Institute of the State of São Paulo for 6 months and will include patients agreeing to voluntary participation upon signing an informed consent form.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Urologic Cancer

Currently open trials in the same condition.

Other Instituto do Cancer do Estado de São Paulo trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06282354.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing